# OnCo record aml-flt3 (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/aml-flt3/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "aml-flt3" ;
  schema:name "FLT3-mutated acute myeloid leukaemia"@en ;
  schema:alternateName "FLT3-ITD AML"@en, "FLT3-TKD AML"@en, "FLT3-positive AML"@en ;
  schema:description "FLT3-mutated acute myeloid leukaemia carries a mutation in a growth-signal receptor that makes the leukaemia relapse quickly. Adding a FLT3 blocker to chemotherapy, midostaurin or quizartinib, lengthens life, and gilteritinib is the standard when the disease comes back."@en ;
  schema:url <https://onco.cc/cancers/aml-flt3/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/CD135> ;
  schema:citation <https://en.wikipedia.org/wiki/CD135>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/> ;
  onco:targets <https://onco.cc/targets/flt3/> ;
  onco:terms <https://onco.cc/terms/flt3-itd-allelic-ratio/>, <https://onco.cc/terms/eln-risk/>, <https://onco.cc/terms/seven-plus-three/> ;
  onco:pipeline <https://onco.cc/drugs/gilteritinib/>, <https://onco.cc/drugs/quizartinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/trials/myelomatch/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/> ;
  onco:standardOfCare <https://onco.cc/drugs/midostaurin/>, <https://onco.cc/drugs/quizartinib/>, <https://onco.cc/drugs/cytarabine-7-3/>, <https://onco.cc/trials/ratify/>, <https://onco.cc/trials/quantum-first/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/pairings/flt3i-plus-7-3/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/gilteritinib/>, <https://onco.cc/trials/viale-a/>, <https://onco.cc/drugs/gilteritinib/>, <https://onco.cc/trials/admiral/>, <https://onco.cc/drugs/quizartinib/>, <https://onco.cc/technologies/allogeneic-hsct/> .